GLUE Relative Valuation
GLUE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GLUE is overvalued; if below, it's undervalued.
Historical Valuation
Monte Rosa Therapeutics Inc (GLUE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.71. The fair price of Monte Rosa Therapeutics Inc (GLUE) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：17.52
Fair
-10.02
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Monte Rosa Therapeutics Inc. (GLUE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -2.25. The thresholds are as follows: Strongly Undervalued below -9.74, Undervalued between -9.74 and -6.00, Fairly Valued between 1.50 and -6.00, Overvalued between 1.50 and 5.25, and Strongly Overvalued above 5.25. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-4.73
EV/EBIT
Monte Rosa Therapeutics Inc. (GLUE) has a current EV/EBIT of -4.73. The 5-year average EV/EBIT is -2.20. The thresholds are as follows: Strongly Undervalued below -8.82, Undervalued between -8.82 and -5.51, Fairly Valued between 1.12 and -5.51, Overvalued between 1.12 and 4.43, and Strongly Overvalued above 4.43. The current Forward EV/EBIT of -4.73 falls within the Historic Trend Line -Fairly Valued range.
32.48
PS
Monte Rosa Therapeutics Inc. (GLUE) has a current PS of 32.48. The 5-year average PS is 9.92. The thresholds are as follows: Strongly Undervalued below -15.74, Undervalued between -15.74 and -2.91, Fairly Valued between 22.74 and -2.91, Overvalued between 22.74 and 35.57, and Strongly Overvalued above 35.57. The current Forward PS of 32.48 falls within the Overvalued range.
-7.52
P/OCF
Monte Rosa Therapeutics Inc. (GLUE) has a current P/OCF of -7.52. The 5-year average P/OCF is -4.94. The thresholds are as follows: Strongly Undervalued below -12.48, Undervalued between -12.48 and -8.71, Fairly Valued between -1.17 and -8.71, Overvalued between -1.17 and 2.60, and Strongly Overvalued above 2.60. The current Forward P/OCF of -7.52 falls within the Historic Trend Line -Fairly Valued range.
43.48
P/FCF
Monte Rosa Therapeutics Inc. (GLUE) has a current P/FCF of 43.48. The 5-year average P/FCF is -2.39. The thresholds are as follows: Strongly Undervalued below -36.50, Undervalued between -36.50 and -19.44, Fairly Valued between 14.67 and -19.44, Overvalued between 14.67 and 31.73, and Strongly Overvalued above 31.73. The current Forward P/FCF of 43.48 falls within the Strongly Overvalued range.
Monte Rosa Therapeutics Inc (GLUE) has a current Price-to-Book (P/B) ratio of 4.24. Compared to its 3-year average P/B ratio of 1.57 , the current P/B ratio is approximately 170.41% higher. Relative to its 5-year average P/B ratio of 1.73, the current P/B ratio is about 144.39% higher. Monte Rosa Therapeutics Inc (GLUE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -20.06%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -17.91% , the current FCF yield is about -100.00% lower.
4.34
P/B
Median3y
1.57
Median5y
1.73
13.21
FCF Yield
Median3y
-20.06
Median5y
-17.91
Competitors Valuation Multiple
The average P/S ratio for GLUE's competitors is 0.00, providing a benchmark for relative valuation. Monte Rosa Therapeutics Inc Corp (GLUE) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 38.54%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of GLUE increased by 148.70% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 29.96 to 68.38.
The secondary factor is the Revenue Growth, contributed 38.54%to the performance.
Overall, the performance of GLUE in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Monte Rosa Therapeutics Inc (GLUE) currently overvalued or undervalued?
What is Monte Rosa Therapeutics Inc (GLUE) fair value?
How does GLUE's valuation metrics compare to the industry average?
What is the current P/B ratio for Monte Rosa Therapeutics Inc (GLUE) as of Dec 05 2025?
What is the current FCF Yield for Monte Rosa Therapeutics Inc (GLUE) as of Dec 05 2025?
What is the current Forward P/E ratio for Monte Rosa Therapeutics Inc (GLUE) as of Dec 05 2025?